- 96.4k views
Beyond Breathless: Innovative Approaches to PAH Management
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
About the Speaker
Dr. Bhagwan Mantri
Consultant Pulmonologist and Critical care specialist
Upcoming Case Discussions
Scale Healthcare Brands with AI-Powered Marketing
The AI revolution in medicine is transforming healthcare, making it smarter and more efficient than ever before. From early disease detection to personalized treatment plans, AI empowers doctors with data-driven insights for better decision-making. Robotic surgeries and AI-assisted diagnostics are enhancing precision and reducing human error. AI also improves patient care through virtual assistants and remote monitoring tools. This technological leap is paving the way for a future where healthcare is more accessible, accurate, and innovative.
Comprehensive Approaches to Pediatric Practice
Comprehensive approaches to pediatric practice emphasize holistic care that integrates early screening, preventive measures, and tailored treatments. These strategies involve using tools like the NISA card for early detection of conditions such as iron deficiency anemia. Regular anthropometric assessments provide insight into growth and development, allowing for early intervention. Incorporating neurodevelopmental screening tools ensures that cognitive, emotional, and physical milestones are monitored effectively. Collaborative care models, including parental involvement and education, support continuous patient engagement. Digital health tools can enhance monitoring and streamline consultations. Multidisciplinary teams can address complex cases more efficiently. Preventive care and health education are prioritized to reduce long-term risks. Comprehensive approaches foster a proactive environment that adapts to each child's needs. The result is improved health outcomes and overall child well-being.
Case Based Discussion on Bronchiolitis
Bronchiolitis is a common respiratory infection in infants and young children, primarily caused by the respiratory syncytial virus (RSV). It presents with nasal congestion, cough, wheezing, and difficulty breathing, often following an upper respiratory infection. Management is largely supportive, focusing on hydration, oxygen therapy, and suctioning nasal secretions. Routine use of bronchodilators, steroids, or antibiotics is not recommended. Severe cases may require hospitalization for respiratory support, such as high-flow nasal cannula or mechanical ventilation. Preventive measures include proper hand hygiene and, in high-risk infants, palivizumab prophylaxis. Prompt recognition and appropriate care are key to reducing complications and improving outcomes.
Diabetic Complications in 12 Questions
Diabetic complications in 12 Questions" is designed to address common concerns related to the long-term effects of diabetes, such as neuropathy, retinopathy, and cardiovascular issues. Through a Q&A format, the session aims to educate participants on prevention, early detection, and management strategies for these complications to improve overall diabetic care.
Management of ICU Delirium
The management of ICU delirium involves a combination of preventive strategies, such as early mobilization, minimizing sedation, and addressing underlying medical causes, to reduce the risk and severity of delirium in critically ill patients. Treatment includes optimizing the patient's environment, using non-pharmacological interventions, and, if necessary, medications to manage symptoms while focusing on long-term cognitive recovery.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Bhagwan Mantri's Talks on Assimilate
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.